A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland
Information source: Hospital for Children and Adolescents, Finland
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Kallmann Syndrome
Intervention: Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below) (Drug)
Status: Enrolling by invitation
Sponsored by: Hospital for Children and Adolescents, Finland
Official(s) and/or principal investigator(s):
Taneli J Raivio, MD PhD, Study Director, Affiliation: Hospital for Children and Adolescents, Helsinki University Central Hospital
Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome
Official title: Kallmann Syndrome in Finland
Study design: Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Primary outcome: Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland
Secondary outcome: epidemiology
Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia
(inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone
deformations, mirror movements, hearing loss and infertility. Objective is to characterize
epidemiology, clinical and genetic features of Kallmann syndrome in Finland.
Minimum age: 15 Years.
Maximum age: N/A.
- Kallmann syndrome
- Age 15 yrs or more
- Severe mental retardation
Locations and Contacts
Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki 00029 HUCH, Finland
Starting date: December 2007
Ending date: December 2025
Last updated: February 13, 2008